ESC 2026: laroprovstat evaluated to close the LDL-C treatment gap
Laroprovstat could address persistent LDL-C treatment gaps, offering a new oral option for patients above recommended targets.
Laroprovstat could address persistent LDL-C treatment gaps, offering a new oral option for patients above recommended targets.